Trials / Withdrawn
WithdrawnNCT02605525
Efficacy and Safety of SM101 in the Treatment of IgA Nephropathy
A Phase 2 Study to Assess the Efficacy and Safety of Intravenous Infusion With Human Soluble Recombinant Fc-gamma Receptor IIB (SM101/BAX 1810) in Subjects With Immunoglobulin A Nephropathy (IgAN)
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Baxalta now part of Shire · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy and safety of SM101 in the treatment of Immunoglobulin A nephropathy (IgAN)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | SM101 | Human soluble recombinant Fcγ Receptor IIB |
| OTHER | Placebo | L-histidine-buffered saline with mannitol, sucrose, and polysorbate 20 |
Timeline
- Start date
- 2015-12-31
- Primary completion
- 2016-11-30
- Completion
- 2016-11-30
- First posted
- 2015-11-16
- Last updated
- 2022-02-07
Source: ClinicalTrials.gov record NCT02605525. Inclusion in this directory is not an endorsement.